 |
|
|
|
|
|
|
| Article 1 to 10 out of 17 concerning Sanofi-aventis Groupe
|
-
Inauguration of the sanofi-aventis Central Anti-Counterfeit Laboratory in Tours
(08 Sep 2008)
The sanofi-aventis Central Anti-Counterfeit Laboratory was officially inaugurated at the Tours pharmaceutical plant (in the Department of Indre-et-Loire, France) by Hervé Novelli, Minister of State to the Minister for the Economy, Industry and ...
-
ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Reduce Drug Realization Time
(27 May 2008)
ThalesNano Inc. and sanofi-aventis R&D announced the signing of a research and development collaboration agreement focusing on continuous process chemistry technologies.The collaboration will focus on the development and implementation of continuous ...
-
Sanofi-aventis enters the Dow Jones Sustainability World Indexes (DJSI World)
(26 Sep 2007)
Sanofi-aventis enters the Dow Jones Sustainability World Indexes (DJSI World), the leading global index tracking the financial performance of the leading sustainability-driven companies worldwide. The DJSI World covers the top 10% of the biggest ...
-
Acambis welcomes sanofi pasteur's dengue vaccine progress
(19 Sep 2007)
Acambis plc welcomes sanofi pasteur's reported progress with a dengue vaccine candidate based on technology licensed from Acambis. Sanofi pasteur, the vaccines division of the sanofi-aventis Group, has announced positive results from Phase 2 trials ...
-
Sanofi Pasteur announces completion of construction of new U.S. influenza vaccine manufacturing facility
(26 Jul 2007)
Sanofi pasteur, the vaccines division of the sanofi-aventis Group, announced today the completion of construction of its new influenza vaccine manufacturing facility that is expected to more than double its production capacity in the United States. ...
-
Acambis signs JE partnership agreement with sanofi pasteur
(16 Feb 2007)
Acambis plc announced a partnership agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group, for ChimeriVax(TM)-JE, Acambis' single-dose vaccine against Japanese encephalitis (JE).Under the agreement, Acambis has granted ...
-
Aureus Pharma, ChemAxon, Budapest University of Technology and sanofi-aventis Collaborate on European Toxicity Project
(18 May 2006)
Aureus Pharma and ChemAxon announced that they have been awarded a European Eureka project along with pharmaceutical partner sanofi-aventis and academic partner Budapest University of Technology and Economics. The goal of the project KnowTox® is to ...
-
Sanofi-aventis And Bristol-Myers Squibb Announce Agreement To Settle U.S. Plavix Litigation With Apotex
(23 Mar 2006)
Sanofi-aventis and Bristol-Myers Squibb Company announced that they have reached an agreement subject to certain conditions with Apotex Inc. and Apotex Corp. to settle the patent infringement lawsuit pending between the parties in the U.S. District ...
-
Pfizer and Sanofi-Aventis Statement on Status of Exubera
(01 Nov 2005)
Pfizer and sanofi-aventis, a member of the sanofi-aventis Group, said that the U.S. Food and Drug Administration has notified the companies that it is extending its original review period for Exubera® (insulin [rDNA origin] powder for oral ...
-
Aureus Pharma extends collaboration with Sanofi-Aventis
(13 Jun 2005)
Aureus Pharma, a provider of knowledge management solutions to aid discovery in the life sciences industry, announced that sanofi-aventis has become its first customer for the company's recently released AurSCOPE® Ion Channel database. This ...
|
|
|
|
|
Top